Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (12)

« Back to Publications

Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data.

Pearson C. et al, (2026), Lancet Oncol

Modelled impact of a multi-cancer early detection screening programme on the demand for diagnostics in England

Martin J. et al, (2026), British Journal of Cancer

Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England.

Jones DA. et al, (2025), Br J Haematol, 206, 531 - 540

Individualised Estimation of Quality-adjusted Survival Benefit and Cost-effectiveness of Proton Beam Therapy in Intermediate-stage Hodgkin Lymphoma.

Jones DA. et al, (2023), Clin Oncol (R Coll Radiol), 35, 301 - 310

P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England

Jones D. et al, (2022), HemaSphere, 6, 43 - 44

Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry.

Jones DA. et al, (2022), Blood Adv, 6, 909 - 919

A Systematic Review of Health Economic Evaluations of Proton Beam Therapy for Adult Cancer: Appraising Methodology and Quality

JONES D. et al, (2019), Clinical and Translational Radiation Oncology

A Systematic Review of Health Economic Evaluations of Proton Beam Therapy for Adult Cancer: Appraising Methodology and Quality

GRAY A. et al, (2019), Clinical and Translational Radiation Oncology

Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial

GRAY A. and JONES D., (2019), European Journal of Cancer

Cisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-positive oropharyngeal cancer (HPV+OPC)

Jones DA. et al, (2019), Annals of Oncology, 30, v450 - v451

Analysis of hydration and antiemetics policies in preventing cisplatin-related gastrointestinal and renal toxicities in low-risk human papillomavirus positive-oropharyngeal cancer (HPV+OPC) patients undergoing chemoradiation in De-ESCALaTE trial.

Kong AH. et al, (2019), Journal of Clinical Oncology, 37, 6076 - 6076

Cisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-positive oropharyngeal cancer (HPV plus OPC)

Jones DA. et al, (2019), ANNALS OF ONCOLOGY, 30